Amicus Piggybacks Off Galafold Commercial Infrastructure For Pombiliti + Opfolda Launch
Executive Summary
The company anticipates potential sales in excess of $1bn for the late-onset Pompe disease drug by the end of the decade.
You may also be interested in...
Finance Watch: Public Companies Pursue All Options To Fund R&D, Launches
Public Company Edition: Follow-on offerings may not be the favored path to funding development programs or product launches after major milestones in the current environment. Amicus secured $430m in a deal with Blackstone, while OPKO’s Modex garnered up to $168m from BARDA.
Amicus Wins English Funding For Pombiliti/Opfolda, Immunocore To Appeal Kimmtrak Rejection
Amicus is launching its Pompe disease treatment Pombiliti/Opfolda in the UK after announcing on the same day that it had secured reimbursement and marketing approval for the combination treatment. Meanwhile, Immunocore says it disagrees with NICE's rejection of its advanced uveal melanoma drug, Kimmtrak.
Amicus To See If Its Fabry Drug Galafold Can Benefit From Mis-Diagnosed MS
Rare disease specialist Amicus Therapeutics' lead product Galafold has recently launched with early success and the company's president tells Scrip further momentum could come from better Fabry disease diagnosis.